Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 3/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188460 | 0.96 | CTSK (0.44) | CTSKCTSBCTSSUTS2RTACR2 | |
| SCHEMBL4183416 | 0.92 | CTSK (0.48) | CTSKCTSBCTSSUTS2RTACR2 | |
| SCHEMBL4178394 | 0.92 | CTSK (0.48) | CTSKCTSBCTSSUTS2RTACR2 | |
| SCHEMBL4185942 | 0.92 | CTSK (0.48) | CTSKCTSBCTSSUTS2RTACR2 | |
| SCHEMBL4188439 | 0.92 | CTSK (0.48) | CTSKCTSBCTSSUTS2RTACR2 | |
| SCHEMBL4171105 | 0.92 | CTSB (0.44) | CTSKCTSBCTSSTACR2 | |
| SCHEMBL4191791 | 0.90 | CTSB (0.42) | CTSKCTSBCTSSUTS2RTACR2 | |
| SCHEMBL4178278 | 0.89 | CTSB (0.40) | CTSKCTSBCTSSUTS2RTACR2 | |
| SCHEMBL4192520 | 0.88 | CTSB (0.40) | CTSKCTSBCTSSTACR2CTDSP1 | |
| SCHEMBL4194752 | 0.88 | CTSK (0.51) | CTSKCTSBCTSSUTS2RTACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | claimed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | CTSK 1738/4885CTSB 2311/4885CTSS 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.